Rhythm Pharmaceuticals Files 8-K: Material Definitive Agreement

TL;DR

Rhythm Pharma just signed a big deal, check the 8-K for details.

AI Summary

On April 15, 2024, Rhythm Pharmaceuticals, Inc. entered into a Material Definitive Agreement, the specifics of which are detailed in the filing. This event also constitutes Material Modifications to Rights of Security Holders and potentially involves Amendments to Articles of Incorporation or Bylaws, alongside other events and financial statements/exhibits.

Why It Matters

This filing indicates a significant new agreement for Rhythm Pharmaceuticals, which could impact its operations, financial standing, and the rights of its security holders.

Risk Assessment

Risk Level: medium — Material Definitive Agreements can introduce significant new risks or opportunities, requiring careful review of the terms.

Key Players & Entities

• Rhythm Pharmaceuticals, Inc. (company) — Registrant
• April 15, 2024 (date) — Date of earliest event reported

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share RYTM The Nasdaq
• $150,000,000 — k"), for an aggregate purchase price of $150,000,000, or $1,000 per share (the "Issuance").
• $1,000 — gate purchase price of $150,000,000, or $1,000 per share (the "Issuance"). On April 1

Filing Documents

• tm2411919d1_8k.htm (8-K) — 29KB
• tm2411919d1_ex3-1.htm (EX-3.1) — 372KB
• tm2411919d1_ex3-1img001.jpg (GRAPHIC) — 2KB
• 0001104659-24-047492.txt ( ) — 639KB
• rytm-20240415.xsd (EX-101.SCH) — 3KB
• rytm-20240415_lab.xml (EX-101.LAB) — 33KB
• rytm-20240415_pre.xml (EX-101.PRE) — 22KB
• tm2411919d1_8k_htm.xml (XML) — 4KB

01. Entry into a Material Definitive Agreement

Item 1.01. Entry into a Material Definitive Agreement. As previously disclosed in a Current Report on Form 8-K filed by Rhythm Pharmaceuticals, Inc. (the "Company") with the Securities and Exchange Commission on April 1, 2024 (the "Original 8-K"), on April 1, 2024, the Company entered into an Investment Agreement (the "Investment Agreement") with certain affiliates of Perceptive Advisors LLC ("Perceptive") and certain other investors (each, an "Investor" and collectively, the "Investors"), relating to the issuance and sale of 150,000 shares of a new series of the Company's Series A Convertible Preferred Stock, par value $0.001 per share, titled the "Series A Convertible Preferred Stock" (the "Convertible Preferred Stock"), for an aggregate purchase price of $150,000,000, or $1,000 per share (the "Issuance"). On April 15, 2024, the closing of the Issuance (the "Initial Issue Date") took place, and the Company entered into that certain Registration Rights Agreement with the Investors, pursuant to which the Company granted the Investors certain customary registration rights with respect to the shares of the Company's common stock, par value $0.001 per share (the "Common Stock"), issuable upon conversion of Convertible Preferred Stock. The foregoing description of the Registration Rights Agreement is not complete and is qualified in its entirety by reference to the form of Registration Rights Agreement, which is which is attached as Exhibit B to Exhibit 10.1 to the Original 8-K, and is incorporated herein by reference.

03. Material Modification to Rights of Security Holders

Item 3.03. Material Modification to Rights of Security Holders. The information contained below in Item 5.03 regarding the Certificate of Designations is incorporated into this Item 3.03 by reference.

03. Amendments to Articles of Incorporation or Bylaws; Change

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. In connection with the Initial Issue Date, on April 15, 2024, the Company filed the Certificate of Designations with the Secretary of State of the State of Delaware, effective the same day. As previously disclosed, the Convertible Preferred Stock will rank senior to the shares of the Company's Common Stock, with respect to the payment of dividends and the distribution of assets upon a liquidation, dissolution or winding up of the Company. The Convertible Preferred Stock will initially have a liquidation preference of $1,000 per share; provided that the liquidation preference in dissolution or upon a change of control shall be increased to be 175% of the then applicable liquidation preference, as described in the Certificate of Designations. Holders of the Convertible Preferred Stock will be entitled to a regular dividend (the "Dividend"), at the rate of, (a) for the period beginning on, and including, the Initial Issue Date and ending on, but excluding, the second anniversary of the Initial Issue Date, 0.00% per annum and (b) for the period beginning on, and including, the second anniversary of the Initial Issue Date, six percent 6.00% per annum, compounding quarterly, paid-in-kind or paid in cash, at the Company's election. For any quarter in which the Company elects not to pay the Dividend in cash with respect to a share of Convertible Preferred Stock, such Dividend will become part of the liquidation preference of such share, as set forth in the Certificate of Designations. In addition, no dividend or other distribution on the Common Stock will be declared or paid on the Common Stock unless, at the time of such declaration and payment, an equivalent dividend or distribution is declared and paid on the Convertible Preferred Stock. The foregoing description Certificate of Designations is not complete and is qualified in its entirety by reference to the full text of such document

01. Other Events

Item 8.01. Other Events. The information contained in Items 1.01 and 5.03 regarding the Initial Issue Date is incorporated into this Item 8.01 by reference.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 3.1 Certificate of Designations 104 Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. RHYTHM PHARMACEUTICALS, INC. Date: April 16, 2024 By: /s/ Hunter Smith Hunter Smith Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR